What is the rating for PCVX stock?

Vaxcyte, Inc. (PCVX) has a "Reduce" rating based on our 6-factor quantitative model. It has a composite score of 44.4 and ranks #2900 out of 7,333 stocks in our coverage universe with a 2-star rating.

Is PCVX a good stock to buy?

Based on our quantitative analysis, PCVX receives a "Reduce" rating with 2 out of 5 stars. Key factors include: Quality score of 30.7, Value score of 32, and Momentum score of 48.3. The timing score is 57, indicating "Favorable" entry conditions. This is not investment advice - please conduct your own research.

What sector is PCVX in?

Vaxcyte, Inc. (PCVX) operates in the Manufacturing sector, specifically in the Pharmaceutical Products industry. It has a market capitalization of $4.68 billion.

What is PCVX's P/E ratio?

P/E ratio data is not currently available for PCVX.

Does PCVX pay a dividend?

PCVX does not currently pay a dividend.

What is PCVX's market cap?

Vaxcyte, Inc. (PCVX) has a market capitalization of $4.68 billion, making it a mid-cap stock.

What are the risks of investing in PCVX?

Key risk factors for PCVX include: notable short interest, and general market risk. As with all investments, there is risk of loss.

How does PCVX compare to peers?

Within the Manufacturing sector, PCVX ranks #2900 overall with a quality score of 30.7/100 and value score of 32/100.

What is PCVX's revenue growth?

Revenue growth data is not currently available for PCVX.

What is PCVX's composite score?

Vaxcyte, Inc. (PCVX) has a composite score of 44.4/100, which places it at rank #2900 out of 7,333 stocks. This score is derived from our proprietary 6-factor quantitative model that evaluates quality, value, momentum, investment efficiency, stability, and short interest.

How does PCVX compare to the S&P 500?

PCVX ranks in the top 60% of all stocks in our coverage universe with a composite score of 44.4.

What are the bull and bear cases for PCVX?

Bull case: PCVX scores highest in stability at 52.4/100, indicating strong performance in this area. Bear case: The weakest factor is quality at 30.7/100, which may present a risk. Our overall assessment is Reduce with 2 out of 5 stars.

Is PCVX overvalued or undervalued?

PCVX appears overvalued based on our value factor score of 32/100.

What is PCVX's momentum score?

PCVX has a momentum score of 48.3/100, placing it in the moderate category.

When is PCVX's next earnings date?

For the latest earnings date and analysis for PCVX, visit our earnings calendar or check the PCVX stock page for real-time updates. Our AI-generated earnings reports provide in-depth analysis after each quarterly report.

Is PCVX a good stock to buy right now?

Based on our 6-factor quantitative model, Vaxcyte, Inc. (PCVX) receives a "Reduce" rating with a composite score of 44.4/100. It is ranked #2900 out of 7,333 stocks. Key factor scores: Quality 31/100, Value 32/100, Momentum 48/100. The timing signal is "Favorable". This is quantitative analysis only — not investment advice.

What is the stock rating for PCVX?

Vaxcyte, Inc. (PCVX) has a "Reduce" rating and 2-star score. The composite score of 44.4 ranks it #2900 among 7,333 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is PCVX in?

Vaxcyte, Inc. operates in the Manufacturing sector (Pharmaceutical Products industry) with a market cap of $4.68 billion. It is classified as a mid-cap stock.

Does PCVX pay a dividend?

PCVX does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is PCVX's P/E ratio?

P/E ratio data is not currently available for PCVX, which may indicate the company is not yet profitable.

How profitable is PCVX?

PCVX's quality factor score is 31/100. ROE: -21.5% vs sector average -1.9%. Margins are moderate to low, reflecting competitive market dynamics.

How is PCVX valued compared to peers?

PCVX's value factor score is 32/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is PCVX's debt level?

PCVX's debt-to-equity ratio is 10%. Sector average: 0%. Low leverage suggests conservative financial management.

PCVX has a beta of 0.78, meaning it is less volatile than the market. Stability score: 52/100.

Does PCVX have high short interest?

PCVX's short interest factor score is 34/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

PCVX Stock Analysis — Vaxcyte, Inc. Price Target & Forecast 2026

IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.

HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.

RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.

PCVX Stock Analysis — Vaxcyte, Inc. Price Target & Forecast 2026 | Blank Capital Research

Sector

Manufacturing

Industry

Pharmaceutical Products

Market Cap

$4.7B

Leadership

Grant E. Pickering

Business Summary

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials. The company was formerly known as SutroVax, Inc.

Operations

Headcount

160

Location

HQ Base

Pending Verification

Investor Relations

Fundamental Spot Check

Context: 2025

Valuation

Market Cap

$4.7B

P/E Ratio

P/B Ratio

2.90xLagging

P/S Ratio

EV/EBITDA

Dividend Yield

0.00%

Efficiency & Risk

Gross Margin

Operating Margin

ROE

-21.5%Lagging

Rev Growth (YoY)

Debt/Equity

10.00xLagging

Beta

0.78

Red = Sector Laggard

Black = Market Average

Revenue Breakdown

Strategic Timing Audit

WEAK

0/6

Negative Alignment — Extreme Caution

Quantitative Factor Convergence Analysis Verified

Momentum

48th pctl

Intelligence Feed

The Motley FoolJan 1 Neutral

Trump and Interest Rates: The 2 Key Reasons This Vanguard ETF Could Thrive in 2025

The Vanguard Russell 2000 ETF (VTWO) could be a great investment opportunity in 2025 due to potential benefits from the incoming Trump administration's policies and further interest rate cuts from the Federal Reserve.

yahoo5d ago Positive

Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best stocks to buy and hold for the next 6 months. On February 11, Vaxcyte Inc. (NASDAQ:PCVX) confirmed the dosing of the first participants in its OPUS-3 Phase 3 trial. The trial is evaluating the VAX-31 pneumococcal conjugate vaccine in adults who previously received pneumococcal vaccination. VAX-31 is […]

finance.yahoo.com6d ago Neutral

Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Vaxcyte Inc. (NASDAQ:PCVX) closed its public offering of the sale of 12.65 million shares of the company’s common stock at $50 per share, raising $632.5 million in gross proceeds in the process. The offering included […]

BenzingaFeb 2 Neutral

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte, Inc. (NASDAQ: PCVX) announced the successful closing of its underwritten public offering, raising $632.5 million gross proceeds through the sale of 12,650,000 shares of common stock at $50 per share, including the full exercise of underwriters' option for 1,650,000 additional shares. The funds will support the company's clinical-stage vaccine development programs.

The Motley FoolAug 7 Positive

Vaxcyte (PCVX) Q2 Loss Widens 11%

Vaxcyte reported a wider Q2 2025 net loss of $1.22 per share, driven by increased R&D and G&A expenses. The company advanced its VAX-31 vaccine program with FDA Breakthrough Therapy Designation and has $2.8 billion in cash to fund operations through mid-2028.

Earnings Call Transcripts

Unlock Valuation Tools

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Financial Intelligence Ledger

Verified SEC Filings Aggregate • PCVX

Export

Metric Entity	10Y Historical Trend	2024	2023	2022	2021	2020	2019
Revenue		$0	$0	$0	$0	$0	$0
Cost of Revenue	-	—	—	—	—	—	—
Gross Profit		—	—	—	—	$0	$0
R&D Expense		$477M43.4%	$332M96.1%	$169M116.1%	$78M6.6%	$74M61.3%	$46M
Operating Expenses	-	—	—	—	—	—	—
Operating Income		-$570M21.7%	-$468M101.5%	-$232M124.0%	-$104M15.7%	-$90M65.4%	-$54M
Interest Expense		—	$0	$2K71.4%	$7K0.0%	$7K82.5%	$40K
Tax Provision	-	—	—	—	—	—	—
EBITDA		-$563M21.0%	-$465M102.4%	-$230M125.4%	-$102M15.7%	-$88M79.0%	-$49M
Net Income		-$464M15.3%	-$402M80.0%	-$223M123.3%	-$100M12.2%	-$89M77.5%	-$50M
EPS (Diluted)		$-3.808.2%	$-4.1420.3%	$-3.44	-	$-3.0277.2%	$-13.25

SEC EDGAR Repository

Direct unfiltered access to 10-K, 10-Q and 8-K filings for PCVX.

Open Regulatory Dossier

Data Integrity Notice

Figures adjusted for stock splits and restatements where applicable.

TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.

Execution Benchmarks Audit

Return on Equity

Equity efficiency

+1034% SCTR

-21.5%

Sector Avg: -1.9%

Debt/Equity

Financial leverage

-4662% SCTR

10.0%

Sector Avg: 0.2%

Dividend Yield

Direct cash return

-NaN% SCTR

0.0%

Sector Avg: 0.0%

Financial History

Forensic Accounting Audit

Verified

Insufficient data for Financial Analysis

Algorithmic red flag detection based on regulatory SEC filings.

Unlock Financial Statements

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Shareholder Returns

Capital Allocation audit

Smart Money Conviction

Neutral

Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.

Governance Audit

Weak Index

WeakModerateStrong

Lower quality and stability scores may indicate governance concerns. Verified against factor-based integrity benchmarks.

Executive Operations

CEO: Grant E. Pickering

Insider alignment Audit

No recent insider transactions available for PCVX

Major Institutional Blocks

Top 5 Holders

Institutional cap table data requires verified 13F filing feeds.

Access SEC 13F Dossier →

Form 4 Filings

Recent Activity

Insider transaction data currently awaiting regulatory verification.

Access SEC Form 4 Dossier →

Regulatory Disclosure Vault

Proxy Statement (DEF 14A)

Exec Comp, Board Nominees, Proposals

Annual Report (10-K)

MD&A, Risk Factors, Strategy

Institutional Holders (13F)

Loading institutional data...

Insider Liquidity

Short Interest audit

SEC Risk Factors

Unlock Governance & Ownership

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Factor Analysis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Investment Thesis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Institutional Peer Matrix

Top Manufacturing Universe

Stock	Rating	Score▼	Quality	Value	Momentum	P/E	EV/EBITDA	ROE	ROA	Gross Mgn	Op Mgn	Net Mgn	Rev Growth	Div Yield	D/E	Mkt Cap	AUDIT
$UL UNILEVER PLC		78	96	98	59	-	-	-	-	-	-	-	-	-	-	$0	VS
$ASML ASML HOLDING NV		77	89	86	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$ESLT ELBIT SYSTEMS LTD		76	81	87	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$MT ArcelorMittal		75	71	98	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$AMAT APPLIED MATERIALS INC /DE		75	85	87	84	20.9x	13.6x	32.9%	20.5%	48.8%	30.6%	24.4%	7.7%	0.9%	32.0x	$148.6B	VS
$SIMO Silicon Motion Technology CORP		75	84	86	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$CODA Coda Octopus Group, Inc.		74	83	90	79	16.3x	11.9x	7.4%	7.5%	68.3%	19.5%	18.2%	29.0%	0.0%	0.0x	$84M	VS
$GSK GSK plc		74	84	90	70	-	-	-	-	-	-	-	-	-	-	$0	VS
$EFXT Enerflex Ltd.		74	80	91	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$BUD Anheuser-Busch InBev SA/NV		74	84	97	63	-	-	-	-	-	-	-	-	-	-	$0	VS
$PCVX Vaxcyte, Inc.		44	31	32	48	-	-	-21.5%	-19.7%	-	-	-	-	0.0%	10.0x	$4.7B
SECTOR BENCH	-	-	-	-	-	22.3x	11.5x	-1.9%	0.9%	44.1%	2.5%	1.0%	6.7%	0.0%	0.2x	-	REF

Access Full Manufacturing Intelligence Archive →

Lateral Comparison Mesh

$PCVX / $UL AUDIT $PCVX / $ASML AUDIT $PCVX / $ESLT AUDIT $PCVX / $MT AUDIT $PCVX / $AMAT AUDIT

Market Intelligence FAQ

Vaxcyte, Inc. (PCVX) receives a "Reduce" rating with a composite score of 44.4/100. It ranks #2900 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.

Full Research Publication

Equity Research Analysis: Vaxcyte, Inc. (PCVX)

FEBRUARY 2026|Blank Capital Research Unit|Spot: $61.35

Price$61.35

Composite Score44.4/100

RatingREDUCE (2★)

Rank#2900 OF 7,333

Market Cap$4.7B

ROE

Comments

Institutional Audit

Feb 25, 2026

Vaxcyte, Inc.

44.4

Executive Summary

Vaxcyte, Inc. receives a Reduce rating from our analysis, with a composite score of 44.4/100 and 2 out of 5 stars, ranking #2900 out of 7,333 stocks. PCVX's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.

Business Quality

PCVX's quality score of 31/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -21.5% (sector avg: -1.9%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.

Intrinsic Valuation

With a value score of 32/100, PCVX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 2.90x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.

Capital Reinvestment

With an investment score of 44/100, PCVX exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of -19.7% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.

Market Momentum

PCVX is currently showing below-average momentum at 48/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.78 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.

Balance Sheet Health

With a stability score of 52/100, PCVX exhibits average financial resilience. Key stability metrics include a beta of 0.78 and a debt-to-equity ratio of 10.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.

Institutional Risk Profile

Vaxcyte, Inc.'s short interest score of 34/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 10.00x). At $4.7B (mid-cap), PCVX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.

Sector Benchmark Analysis

Vaxcyte, Inc. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2900 of 7,333 overall (60th percentile). Key comparisons include ROE of -21.5% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.

Comparative Research Mesh

PCVX VS S&P 500 (SPY)TOP MANUFACTURING PEERS

Strategic Alternatives

While PCVX currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.

View Top Manufacturing Alpha →

PCVX

Vaxcyte, Inc.

Business Summary

Operations

Location

Fundamental Spot Check

Valuation

Efficiency & Risk

Intelligence Feed

Trump and Interest Rates: The 2 Key Reasons This Vanguard ETF Could Thrive in 2025

Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials

Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte (PCVX) Q2 Loss Widens 11%

Unlock Valuation Tools

Unlock Financial Statements

Unlock Governance & Ownership

Unlock Factor Analysis

Unlock Investment Thesis

Lateral Comparison Mesh

Comments

Unlock Performance & Technicals

Economic Moat Audit

Economic Value Creation

Margin Superiority

Reinvestment Efficiency

Growth Durability

Financial Resilience

Uncertainty Audit

BEAR THESIS

01Executive Summary

02Strategy & Outlook

Risk / Reward Variance

Research Verdict

Related Stocks

Executive Summary

Business Quality

Intrinsic Valuation

Capital Reinvestment

Market Momentum

Balance Sheet Health

Institutional Risk Profile

Sector Benchmark Analysis

Comparative Research Mesh

Strategic Alternatives

Factor Dispersion Audit

Sector Variance Findings

Market Intel

Intelligence Feed

Trump and Interest Rates: The 2 Key Reasons This Vanguard ETF Could Thrive in 2025

Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials

Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte (PCVX) Q2 Loss Widens 11%